Premium
Adenosine receptors and human melanoma
Author(s) -
Merighi Stefania,
Baraldi Pier Giovanni,
Gessi Stefania,
Iannotta Valeria,
Klotz KarlNorbert,
Leung Edward,
Mirandola Prisco,
Tabrizi Mojgan Aghazadeh,
Varani Katia,
Borea Pier Andrea
Publication year - 2003
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.10181
Subject(s) - adenosine , adenosine receptor , receptor , adenosine a2b receptor , purinergic signalling , adenosine a3 receptor , microbiology and biotechnology , signal transduction , biology , kinase , stimulation , extracellular , protein kinase a , cancer research , pharmacology , endocrinology , biochemistry , agonist
Increased concentrations of extracellular adenosine are reached in ischemic or inflamed tissues but have also been detected inside tumoral masses. This latter finding may account for an important role of adenosine in the pathogenesis of tumors and its contradictory effects on cell survival and proliferation remain to be reconciled with the presence of specific adenosine receptor subtypes. This article reviews the pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line and the functional significance of their presence in a tumor cell type. We show that adenosine improves cell proliferation via A 2A receptors while it arrests the cells at G 1 /G 0 cell cycle phase through A 3 stimulation. Furthermore, adenosine triggers a survival signal via A 3 receptor stimulation while it simultaneously promotes cell death via A 2A receptor activation, inducing a signaling pathway that involves protein kinase C (PKC) and mitogen‐activated protein kinases (MAPKs). Drug Dev. Res. 58:377–385, 2003. © 2003 Wiley‐Liss, Inc.